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Constitutive activityThe melanocortin-4 receptor (MC4R) is a G protein-coupled receptor that plays an essential role in regulating
energy homeostasis. Defects in MC4R are the most common monogenic form of obesity, with about 170 dis-
tinct mutations identiﬁed in human. In addition to the conventional Gs-stimulated adenylyl cyclase pathway,
it has been recently demonstrated that MC4R also activates mitogen-activated protein kinases, extracellular
signal-regulated kinases 1 and 2 (ERK1/2). Herein, we investigated the potential of four MC4R ligands that
are inverse agonists at the Gs-cAMP signaling pathway, including agouti-related peptide (AgRP), MCL0020,
Ipsen 5i and ML00253764, to regulate ERK1/2 activation (pERK1/2) in wild type and six naturally occurring
constitutively active mutant (CAM) MC4Rs. We showed that these four inverse agonists acted as agonists for
the ERK1/2 signaling cascade in wild type and CAMMC4Rs. Three mutants (P230L, L250Q and F280L) had sig-
niﬁcantly increased pERK1/2 level upon stimulation with all four inverse agonists, with maximal induction
ranging from 1.6 to 4.2-fold. D146N had signiﬁcantly increased pERK1/2 level upon stimulation with AgRP,
MCL0020 or ML00253764, but not Ipsen 5i. The pERK1/2 levels of H76R and S127L were signiﬁcantly in-
creased only upon stimulation with AgRP or MCL0020. In summary, our studies demonstrated for the ﬁrst
time that MC4R inverse agonists at the Gs-cAMP pathway could serve as agonists in the MAPK pathway.
These results suggested that there were multiple activation states of MC4R with ligand-speciﬁc and/or
mutant-speciﬁc conformations capable of differentially coupling the MC4R to distinct signaling pathways.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
G protein-coupled receptors (GPCRs) are versatile signaling mole-
cules that regulate almost all physiological processes including ener-
gy homeostasis [1]. The melanocortin-4 receptor (MC4R) is a member
of family A GPCRs that has been shown to be a critical regulator of en-
ergy homeostasis, regulating both energy intake and expenditure
[2,3]. Human genetic studies have identiﬁed that defects in MC4R
are the commonest monogenic form of obesity, characterized by its
early-onset and severity [4]. About 170 MC4R mutations, including
nonsense, missense, frameshift, and inframe deletions, have been
identiﬁed from obese patient cohorts of different ethnic origins [5–7].
Since the cloning of the MC4R by Gantz et al. in 1993 [8], it has
been established that it primarily couples to the stimulatory G protein
(Gs), which increases adenylyl cyclase activity, and subsequently
leads to increased cyclic AMP (cAMP) production that then enhances
the activity of protein kinase A (PKA). The activation of MC4R by the
endogenous agonist, α-melanocyte stimulating hormone (α-MSH),
results in decreased food intake and increased energy expenditure,Physiology and Pharmacology,
University, Auburn, AL 36849,
rights reserved.while the inhibition of MC4R by the endogenous antagonist, agouti-
related protein (AgRP), leads to increased food intake [9,10].
Previous functional studies ofMC4R on both naturally occurring and
laboratory-generated mutants have relied primarily on measurements
of intracellular cAMP generation. For example, studies on the naturally
occurringmutations identiﬁed somemutationswith defects in intracel-
lular cAMP signaling (reviewed in [5–7,11]). However, some mutants
show no functional alterations on intracellular cAMP accumulation
[12–15], and some mutants even constitutively activate cAMP produc-
tion [16,17]. Six naturally occurring mutations identiﬁed in obese pa-
tients, including H76R [15,18], S127L [14,19], D146N [15,18], P230L
[14,19], L250Q [16,20,21] and F280L [15,22] (Fig. 1), have been shown
to cause constitutive activation. The obesity observed in vivo in these
patients could not easily be explained by the in vitro cellular phenotype
of these mutations. Indeed, gain of function mutation is expected to re-
sult in lean phenotype, even anorexia nervosa. This suggests that signal-
ing pathways other than Gs might contribute to the physiological effect
of the MC4R. Indeed, in addition to the conventional Gs-cAMP–PKA
pathway, it has been demonstrated recently that MC4R also activates
p44/42 mitogen-activated protein kinases (MAPK), also known as ex-
tracellular signal-regulated kinases 1 and 2 (ERK1/2), both in vitro
and in vivo in rat hypothalamus [23–25]. It has also been demonstrated
that ERK1/2 is involved in melanocortin-induced decreases in food in-
take [26]. Thus, activation of ERK1/2 pathway is one cellularmechanism
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Fig. 1. Schematic model of the hMC4R. The naturally occurring constitutively active mutations characterized in this study are highlighted with gray background.
1940 X.-L. Mo, Y.-X. Tao / Biochimica et Biophysica Acta 1832 (2013) 1939–1948that may underlie the regulation of energy homeostasis mediated by
the MC4R.
Recently, a few studies discovered the biased activation of ERK1/2
in MC4R. It has been shown that one mutant MC4R (D298N) retains
cAMP generation but abolishes ERK1/2 activation [27]. We also
reported that several artiﬁcially generated mutant MC4Rs have
divergent cAMP and ERK1/2 signaling cascades upon agonist stimu-
lation [28,29]. However, little is known about the alteration of ERK1/
2 pathway in naturally occurring MC4R mutants, and how MC4R
ligands may regulate the ERK1/2 signaling cascade that is crucial
to gain a better understanding of MC4R functions at the molecular
basis. In the present study, we assessed the potential of MC4R
ligands, particularly antagonists, to regulate MAPK activation inA: AgRP (83-132)
B: MCL0020 C: Ipsen 5i
Fig. 2. Amino acid sequence of AgRP(83–132) (A) and chemical swild type (WT) and the six naturally occurring constitutively active
mutant (CAM) MC4Rs.
2. Materials and methods
2.1. Reagents and supplies
[Nle4, D-Phe7]-α-melanocyte stimulating hormone (NDP-α-MSH)
and AgRP(83–132) (Fig. 2A) were purchased from Peptides Interna-
tional (Louisville, KY). Ac-D-2-Nal-Arg-2-Nal-NH2 (MCL0020) [30]
(Fig. 2B) was purchased from Tocris Bioscience (Ellisville, MO). Ipsen
5i [31] (Fig. 2C) and ML00253764 [32] (2-[2-[2-(5-bromo-2-methoxy-
phenyl)-ethyl]-3-ﬂuorophenyl]-4,5-dihydro-1H-imidazol) (Fig. 2D)D: ML00253764
tructures of MCL0020 (B), Ipsen 5i (C) and ML00253764 (D).
1941X.-L. Mo, Y.-X. Tao / Biochimica et Biophysica Acta 1832 (2013) 1939–1948were custom synthesized by Enzo Life Science, Inc. (Plymouth Meeting,
PA). [125I]-cAMPwas iodinated using chloramine Tmethod. Cell culture
plates and ﬂasks were purchased from Corning (Corning, NY). Cell cul-
turemedia, newborn calf serum, antibiotics and reagentswere obtained
from Invitrogen (Carlsbad, CA).
2.2. Cell culture and DNA transfection
HEK293T cells were obtained from the American Type Culture
Collection (Manassas, VA), and maintained at 5% CO2 in Dulbecco's
modiﬁed Eagle's medium containing 10 mM HEPES, 10% newborn calf
serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml
amphotericin B and 50 μg/ml gentamicin. Cells were plated on
gelatin-coated 35 mm 6-well clusters and transfected at 50–70%
conﬂuency using calcium phosphate transfection method. GT1–7
cells were generously provided by Dr. Pamela Mellon [33], and
maintained at 5% CO2 in Dulbecco's modiﬁed Eagle's medium
containing 10 mM HEPES, 10% fetal bovine serum, 100 units/ml
penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B and
50 μg/ml gentamicin. For preparation of cellular lysates for immu-
noblotting, cells were plated on gelatin-coated 100 mm dishes,
then cells were washed twice and incubated with Waymouth/BSA
(Waymouth's MB752/1 media (Sigma-Aldrich, St. Louis, MO) containing
1 mg/ml bovine serum albumin (BSA)) 24 h after transfection (or 48 h
after plating GT1–7 cells) and starved (18 h for HEK293T or 24 h for
GT1–7) at 37 °C before ligand stimulation.
2.3. cAMP accumulation assay
HEK293T cells were washed twice, 48 h after transfection, with
warm Waymouth/BSA and then incubated in fresh Waymouth/BSA
containing 0.5 mM isobutylmethylxanthine (Sigma-Aldrich) at 37 °C
for 15 min. Subsequently, either buffer alone or different ligands
(1 μM NDP-MSH [28], 10 nM AgRP [21], 1 μM MCL0020 [30], 1 μM
ML00253764 [6] or 1 μM Ipsen 5i [21]) were added and the incuba-
tion was continued for another hour. Cells were then solubilized
with cold 0.5 N percholoric acid containing 180 μg/ml theophylline
(phosphodiesterase inhibitor). The supernatant was collected to mea-
sure the level of cAMP production using radioimmunoassay [21,34].
All determinations were performed in triplicate, and each experiment
was performed three times independently.
2.4. ERK1/2 phosphorylation assay
The phosphorylated ERK1/2 (pERK1/2) activity was measured as
described previously [28,29]. Brieﬂy, 48 h after transfection (or 72 h
after plating GT1–7 cells), cells starved overnight (see above) were
treated for 5 min (or various times for time-course study) with either
buffer alone or different ligands (1 μM NDP-MSH, 10 nM AgRP, 1 μM
MCL0020, 1 μM ML00253764 or 1 μM Ipsen 5i). The time points in
the time-course experiments were chosen based on previous reports
of MC4R-mediated ERK1/2 signaling [24,25,35]. Cells were solubilized
in lysis buffer and lysateswere separated on 10% SDS-PAGEgel. Proteins
were then transferred onto PVDF membrane. pERK1/2 and β-tubulin
were detected by immunoblotting with rabbit anti-pERK1/2 antibody
(1:1000 ~ 1:2000, Cell Signaling Technology, Beverly, MA) and mouse
anti-β-tubulin antibody (1:5000 ~ 1:10,000, Developmental Studies
Hybridoma Bank at the University of Iowa, Iowa City, IA), respectively.
Blots were probed with horseradish peroxidase-conjugated secondary
donkey anti-rabbit (1:2000, Jackson ImmunoResearch Laboratories,
West Grove, PA) and horseradish peroxidase-conjugated donkey anti-
mouse (1:5000 ~ 1:10,000, Jackson ImmunoResearch Laboratories) at
room temperature for 2 h. The membranes were then visualized using
enhanced chemiluminescence reagent (Pierce, Rockford, IL) and quan-
tiﬁed using ImageJ 1.44 software (National Institute of Health, Bethesda,
MD) after densitometric scanning of the ﬁlms. ERK1/2 phosphorylationwas normalized according to the loading of proteins by expressing the
data as a ratio of pERK1/2 over β-tubulin.
2.5. Statistics
The signiﬁcance of differences in cAMP accumulation and pERK1/2
activities were analyzed using paired two-tailed Student's t-test with
Prism 4.0 software.
3. Results
3.1. cAMP and pERK1/2 signaling efﬁcacies of MC4R agonist NDP-α-MSH
HEK293T cells lacking endogenous expression of the MC4R have
been widely used as a mammalian expression system in MC4R
studies. We used HEK293T cells transiently transfected with the WT
or CAM hMC4R to study the effect of NDP-α-MSH on the conventional
cAMP pathway. In accordance with our previous reports [14,15,21],
the CAM hMC4Rs had signiﬁcantly increased basal cAMP levels at
2–10-fold that of the WT (Fig. 3A). NDP-α-MSH acted as an agonist
for the WT and CAM hMC4R in the cAMP pathway, inducing signiﬁ-
cantly increased cAMP accumulation (Fig. 3A).
To evaluate the efﬁcacy of NDP-α-MSH on MAPK signaling, we
ﬁrst performed the time-course study of NDP-α-MSH-induced
ERK1/2 phosphorylation in HEK293T cells transiently transfected
with WT hMC4R. We found that NDP-α-MSH behaved as an agonist
inducing a sustained activation of ERK1/2 with a 3-fold maximal
increase at 5 min upon stimulation with 1 μM NDP-α-MSH (Fig. 3B–C).
The activation of ERK1/2 sustained for up to 30 min, and the level of
pERK1/2 decreased to 59% of the maximal response at 60 min, but was
still 1.8-fold higher compared to the basal pERK1/2 level (Fig. 3B–C).
No signiﬁcant change of pERK1/2 level was observed upon NDP-α-NSH
treatment in HEK293T cells transiently transfected with the empty
vector pcDNA3.1 (data not shown).
To exclude artifacts due to overexpression of the MC4R in a non-
neuronal cell line, we also studied the NDP-α-MSH-induced ERK1/2
activation in a mouse hypothalamic cell line, GT1–7, that express
murine (m) MC4R endogenously [36]. Stimulation with 1 μM NDP-α-
MSH induced a 2.3-fold transient activation of pERK1/2 with maximal
response at 5 min (Fig. 3B–C). The level of pERK1/2 quickly decreased
to 60% of basal level after 20 min incubation.
Based on the kinetic proﬁle of ERK1/2 activation in WT MC4R
(Fig. 3B–C), the pERK1/2 levels of the CAM MC4Rs were measured
after 5 min stimulation with NDP-α-MSH in HEK293T cells transient-
ly transfected with CAMMC4Rs. As shown in Fig. 3D–E, we found that
NDP-α-MSH acted as an agonist for ERK1/2 signaling cascade in all
CAM hMC4Rs, inducing signiﬁcantly increased pERK1/2 level upon
5 min NDP-α-MSH stimulation. In addition, we found that all six
CAM hMC4Rs displayed constitutively active basal pERK1/2 signaling
(Fig. 3F). Similar observations were made before in our previous report
that some mutant hMC4Rs with increased basal cAMP production also
have enhanced basal ERK1/2 phosphorylation [29].
3.2. cAMP and pERK1/2 signaling efﬁcacies of peptidic antagonist
AgRP(83–132)
The melanocortin system is unique in having two endogenous
antagonists, agouti and agouti-related protein (AgRP) [6]. AgRP is an
antagonist for the hMC4R. Previous studies have shown that a frag-
ment of AgRP, AgRP(83–132), is an inverse agonist that decrease
basal cAMP signaling of WT or CAM hMC4Rs [21,37,38]. In the present
study, we showed that AgRP(83–132) indeed acted as an inverse ag-
onist, causing 50–80% decrease of basal cAMP level of WT and six
CAM hMC4Rs (Fig. 4A), consistent with previous reports.
Although AgRP(83–132) has been demonstrated to be an inverse
agonist in the cAMP signaling pathway, little is known how it may
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Fig. 3. cAMP and ERK1/2 signaling efﬁcacy of MC4R superpotent agonist NDP-α-MSH. cAMP accumulation (A) and ERK1/2 phosphorylation (B–F) experiments were performed as
described in Materials and methods. A representative blotting of time-course study (B) and kinetics (C) of ERK1/2 phosphorylation carried out in HEK293T and GT1–7 cells.
Representative image (D) and densitometry results (E) of ERK1/2 phosphorylation in HEK293T cells transiently transfected with WT or six CAM MC4Rs. Results are expressed
as percentage of the value obtained in non-stimulated cells and represent the mean ± SEM of three independent experiments. (F) Basal pERK1/2 level of WT and CAM MC4Rs,
and results are expressed as percentage of WT basal pERK1/2 activity (n = 14). The statistical signiﬁcance is indicated as follows: *: signiﬁcantly different from basal cAMP or
pERK activity, p b 0.05; **: signiﬁcantly different from basal cAMP or pERK activity, p b 0.01; ***: signiﬁcantly different from basal cAMP or pERK activity, p b 0.001.
1942 X.-L. Mo, Y.-X. Tao / Biochimica et Biophysica Acta 1832 (2013) 1939–1948regulate the ERK1/2 signaling. To study the effect of AgRP on ERK1/2
phosphorylation, we ﬁrst studied the temporal dependence of pERK1/
2 activity in HEK293T cells transiently transfected with WT hMC4R
treated with 10 nM AgRP(83–132). We found that, interestingly,
AgRP(83–132) acted as an agonist for MAPK cascade, inducing a tran-
sient phosphorylation of ERK1/2 with a 2.3-fold maximal increase at
5 min after stimulation with 10 nM AgRP(83–132) (Fig. 4B–C). The
activity of pERK1/2 decreased to 60% of the maximal response at
10 min and attenuated to almost the basal pERK1/2 level after
45 min. We did not observe a signiﬁcant change of pERK1/2 level
in HEK293T cells transiently transfected with empty vector upon
AgRP(83–132) treatment (data not shown).
Similar kinetic pattern of ERK1/2 phosphorylation was observed
in GT1–7 cells endogenously expressing mMC4R. We found that
AgRP(83–132) behaved as an agonist for ERK1/2 signaling in GT1–7
cells as that in HEK293T cells, inducing a transient maximal response
at 5 min with 2.1-fold increase of pERK1/2 level upon AgRP(83–132)
stimulation (Fig. 4B-C). The level of pERK1/2 decreased to almost the
basal pERK1/2 level after 10 min. The overall identical pattern of
ERK1/2 phosphorylation for both exogenous (HEK293T cells) andendogenous (GT1–7 cells) receptor expression suggested that the
observed ERK1/2 activation upon AgRP(83–132) stimulation was a
physiological response for MC4R, not an artifact of receptor over-
expression in HEK293T cells.
Therefore, in subsequent experiments a stimulation of 5 min with
10 nM AgRP(83–132) was used to study the ERK1/2 signaling in other
CAM hMC4Rs in HEK293T cells. In all six CAM hMC4Rs, we showed
that AgRP(83–132) also acted as an agonist inducing signiﬁcantly
increased (1.6–2.8-fold increase) pERK1/2 level upon5 min stimulation
with AgRP(83–132) (Fig. 4D–E). These results demonstrated that
AgRP(83–132), commonly classiﬁed as inverse agonist for the cAMP
signaling pathway decreasing basal cAMP level, was shown to exert
agonist properties on the MAPK signaling cascade activating the
phosphorylation of ERK1/2 in WT and six CAM hMC4Rs.
3.3. cAMP and pERK1/2 signaling efﬁcacies of peptidomimetic antagonist
MCL0020
MCL0020, a tri-peptide mimetic MC4R antagonist, was ﬁrst
reported to exert its function as a neutral blocker exhibiting
WT H76R S127L D146N P230L L250Q F280L
10 nM AgRP - + - + - + - + - + - + - +
β-tubulin
pERK1/2
β-tubulin
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β-tubulin
pERK1/2
GT 1-7 0 2 5 4520 3010 60 min
HEK293T 0 2 5 4520 3010 60 min
10 nM AgRP
10 nM AgRP
A
C
B
D
E
Fig. 4. cAMP and ERK1/2 signaling efﬁcacy of AgRP(83–132). cAMP accumulation (A) and ERK1/2 phosphorylation (B–E) was performed as described in Materials and methods.
See the legend to Fig. 3 for details.
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pERK1/2
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pERK1/2
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pERK1/2
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HEK293T 0 2 5 4520 3010 60 min1 μM MCL0020
1 μM MCL0020GT 1-7
Fig. 5. cAMP and ERK1/2 signaling efﬁcacy of MCL0020. cAMP accumulation (A) and ERK1/2 phosphorylation (B–E) was performed as described in Materials and methods. See the
legend to Fig. 3 for details.
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1944 X.-L. Mo, Y.-X. Tao / Biochimica et Biophysica Acta 1832 (2013) 1939–1948antidepressant, anxiolytic and anti-stress effect [30]. In the present
study, however, we demonstrated that MCL0020 actually acted as
an inverse agonist decreasing basal cAMP by 46–85% in WT or six
CAM hMC4Rs (Fig. 5A).
The effect of MCL0020 on the MAPK signaling was ﬁrst assessed in
HEK293T cells transiently transfected with WT hMC4R. We showed
that MCL0020, behaving as an agonist, induced a transient phosphor-
ylation of ERK1/2, with 2.7-fold maximal increase at 5 min (Fig. 5B–
C). The pERK1/2 level decreased to 48% of the maximal response at
20 min and returned almost to the basal pERK1/2 level after 45 min
(Fig. 5B–C). No signiﬁcant phosphorylation of ERK1/2 was observed
in HEK293T cells transiently transfected with empty vector upon
MCL0020 treatment (data not shown).
MCL0020 exhibited similar agonist activity for the MAPK signaling
pathway in GT1–7 cells endogenously expressing mMC4R. We showed
that 1 μM MCL0020 induced a transient activation of ERK1/2, with a
maximal 2-fold phosphorylation at 5 min (Fig. 5B–C). Subsequently,
the pERK1/2 activity decreased rapidly to the basal level after 10 min
incubation with MCL0020 (Fig. 5B–C). These results demonstrated
that the ERK1/2 phosphorylation induced byMCL0020was a physiolog-
ical consequence of MC4R and was not due to the overexpression of
receptor in HEK293T cells.
Therefore, 5 min incubation was used for subsequent study of the
effect of MCL0020 in MAPK signaling in six CAM hMC4Rs. We showed
that MCL0020 also exhibit agonist activity for the MAPK signaling in
all six CAM hMC4Rs, inducing signiﬁcantly increased pERK1/2 activity
upon MCL0020 stimulation (Fig. 5D–E). These results suggested that
MCL0020, commonly classiﬁed as neutral antagonist, was shown to ex-
hibit inverse agonist activity for the cAMP signaling pathwaydecreasing
the basal cAMP level, but to behave as an agonist for theMAPK signaling
cascade activating the phosphorylation of ERK1/2 in WT and six CAM
hMC4Rs.H
1
A
C
B
D
E
Fig. 6. cAMP and ERK1/2 signaling efﬁcacy of Ipsen 5i. cAMP accumulation (A) and ERK1/2
legend to Fig. 3 for details.3.4. cAMP and pERK1/2 signaling efﬁcacies of small molecule antagonist
Ipsen 5i
Ipsen 5i, ﬁrst synthesized by Poitout and his colleagues at Ipsen
Research Laboratories, was reported to act as a selective MC4R antag-
onist with 2 nM binding afﬁnity [31]. Here, we showed that Ipsen 5i
was also an inverse agonist for both WT and CAM MC4Rs, with max-
imal inhibition of basal cAMP ranging from 37% to 80% (Fig. 6A) con-
sistent with our previous ﬁndings [21].
Next, we tested the potential of Ipsen 5i to affect the MAPK signaling
in HEK293T cells transiently transfected with WT hMC4R and GT1–7
cells endogenously expressing the mMC4R. We found that the pERK1/2
level had no signiﬁcant differences upon incubation with 1 μM Ipsen 5i
within 1 h in both HEK293T and GT1–7 cells (Fig. 6B–C). Even though
we did not observe the change of MAPK signaling for WT MC4R,
based on the results with the other ligands (NDP-α-MSH, AgRP
and MCL0020), we chose 5 min incubation to study the potential effect
of Ipsen 5i for MAPK signaling of other six CAM hMC4Rs.
As shown in Fig. 6D–E, Ipsen 5i induced signiﬁcant increases of
ERK1/2 phosphorylation in three CAM hMC4Rs (P230L, L250Q and
F280L), acting as an agonist for MAPK cascade. No signiﬁcant differ-
ence was observed for other three CAM hMC4Rs, H76R, S127L and
D146N, upon 5 min treatment with 1 μM Ipsen 5i. These results
demonstrated that Ipsen 5i, normally identiﬁed as an inverse agonist
for cAMP signaling, exhibited agonist activity for MAPK signaling in
some speciﬁc CAM hMC4Rs.
3.5. cAMP and pERK1/2 signaling efﬁcacies of another small molecule
antagonist ML00253764
ML00253764, ﬁrst reported as MC4R antagonist, has been demon-
strated to effectively reduce cancer cachexia [32,39]. Here, weβ-tubulin
pERK1/2
β-tubulin
pERK1/2
GT 1-7 0 2 5 4520 3010 60 min
EK293T 0 2 5 4520 3010 60 min
1 μM Ipsen 5i
1 μM Ipsen 5i
WT H76R S127L D146N P230L L250Q F280L
μM Ipsen 5i - + - + - + - + - + - + - +
β-tubulin
pERK1/2
phosphorylation (B–E) was performed as described in Materials and methods. See the
1945X.-L. Mo, Y.-X. Tao / Biochimica et Biophysica Acta 1832 (2013) 1939–1948showed that ML00253764 behaved as an inverse agonist for both WT
and CAM hMC4Rs, decreasing basal cAMP level from 47% to 82%
(Fig. 7A), consistent with our previous reports [6,21].
The potential of ML00253764 to regulate MAPK signaling was ﬁrst
examined in HEK293T cells transiently transfected with WT hMC4R.
As shown in Fig. 6B–C, ML00253764, acting as an agonist for MAPK
signaling, induced a signiﬁcantly sustained activation of ERK1/2
with 2.9-fold maximal response at 5 min. The ML00253764-induced
pERK1/2 level sustained for up to 1 h, when there was still a 2.0-fold
increase over basal level (Fig. 7B–C). We did not observe signiﬁcant
ERK1/2 activation upon ML00253764 treatment in HEK293T cells tran-
siently transfected with empty vector (data not shown).
In GT1–7 cells, the ML00253764 also acted as an agonist for MAPK
signaling, inducing a transient ERK1/2 phosphorylation with 2.0-fold
maximal response at 5 min (Fig. 7B–C). The level of ML00253764-
induced pERK1/2 returned to the basal level after 20 min incubation
with ML00253764 (Fig. 7B–C). Overall, the patterns of ERK1/2
phosphorylation in HEK293T and GT1–7 cells were similar in terms
of the maximal activation at 5 min, suggesting that the observed
ML00253764-induced ERK1/2 activation was physiological and not
due to receptor overexpression in HEK293T cells. Therefore, 5 min in-
cubation was used subsequently to study the effect of ML00253764 to
regulate MAPK signaling in six CAM hMC4Rs.
As shown in Fig. 7D–E, four CAM hMC4Rs (D146N, P230L, L250Q
and F280L) had signiﬁcantly elevated pERK1/2 level upon 5 min
ML00253764 stimulation, with 2.2–3.6-fold increase in pERK1/2.
However, no signiﬁcant change of pERK1/2 level was observed for the
other two CAM hMC4Rs (H76R and S127L) upon 1 μM ML00253764
treatment (Fig. 7D–E). These results demonstrated that ML00253764,
which is normally classiﬁed as an inverse agonist, was shown to behave
as agonist inducing signiﬁcantly increased pERK1/2 level in WT and
some CAM hMC4Rs.A
C
B
D
E
G
HE
1 μ
Fig. 7. cAMP and ERK1/2 signaling efﬁcacy of ML00253764. cAMP accumulation (A) and E
See the legend to Fig. 3 for details.4. Discussion
In the present study, our results demonstrated that four ligands
that were previously classiﬁed as antagonists or inverse agonists in
terms of the Gs-cAMP cascade, including AgRP, MCL0020, Ipsen 5i,
and ML00253764, exhibited agonist activity on the MAPK pathway.
These ﬁndings are not consistent with the classical description of li-
gand efﬁcacy, in which agonists and antagonists were purely deﬁned
in the scenario of the most common G protein-mediated signaling.
These results are more in accordance with the developing concept
that ligands can exhibit dual efﬁcacy for divergent cellular signaling
pathways, and thus resulting in different physiological functions
(reviewed in [40]).
As summarized in Table 1, our results demonstrated that NDP-α-
MSH acted as balanced agonist activating both cAMP and MAPK
signaling pathways in theWT and all six CAMMC4Rs. Peptidic inverse
agonist AgRP(83–132) and peptidomimetic inverse agonist MCL0020
behaved as biased agonists activating MAPK signaling, whereas de-
creasing cAMP production in WT and six CAMMC4Rs. Small molecule
inverse agonist Ipsen 5i exhibited biased agonist efﬁcacy for MAPK
signaling in three CAM MC4Rs, including P230L, L250Q and F280L.
Another small molecule inverse agonist ML00253764 acted as biased
agonist inducing ERK1/2 phosphorylation in WT and four CAM
MC4Rs, but not H76R or S127L.
NDP-α-MSH has been demonstrated to lead to sustained activa-
tion of ERK1/2 phosphorylation in dose- and time-dependent manner
in CHO cells stably expressing WT hMC4R [24] and in GT1-1 cells en-
dogenously expressing mMC4R [25]. In the present study, we showed
that, in the HEK293T cells transiently transfected with WT hMC4R,
NDP-α-MSH induced a sustained activation of ERK1/2 phosphoryla-
tion. However, we showed that in GT1–7 cells, NDP-α-MSH induced
a more transient ERK1/2 activation, which is different from otherβ-tubulin
pERK1/2
β-tubulin
pERK1/2
T 1-7 0 2 5 4520 3010 60 min
K293T 0 2 5 4520 3010 60 min
1 μM ML00253764
1 μM ML00253764
WT H76R S127L D146N P230L L250Q F280L
M ML00253764 - + - + - + - + - + - + - +
β-tubulin
pERK1/2
RK1/2 phosphorylation (B–E) was performed as described in Materials and methods.
Table 1
The effect of ligands on cAMP and pERK signaling in WT and CAM MC4Rs.
NDP-α-MSH AgRP(83–132) MCL0020 Ipsen 5i ML00253764
cAMP pERK Bias cAMP pERK Bias cAMP pERK Bias cAMP pERK Bias cAMP pERK Bias
WT ↑ ↑ No ↓ ↑ Yes ↓ ↑ Yes ↓ ― No ↓ ↑ Yes
H76R ↑ ↑ No ↓ ↑ Yes ↓ ↑ Yes ↓ ― No ↓ ― No
S127L ↑ ↑ No ↓ ↑ Yes ↓ ↑ Yes ↓ ― No ↓ ― No
D146N ↑ ↑ No ↓ ↑ Yes ↓ ↑ Yes ↓ ― No ↓ ↑ Yes
P230L ↑ ↑ No ↓ ↑ Yes ↓ ↑ Yes ↓ ↑ Yes ↓ ↑ Yes
L250Q ↑ ↑ No ↓ ↑ Yes ↓ ↑ Yes ↓ ↑ Yes ↓ ↑ Yes
F280L ↑ ↑ No ↓ ↑ Yes ↓ ↑ Yes ↓ ↑ Yes ↓ ↑ Yes
The column “Bias” is designated for whether the ligand-induced cAMP and pERK1/2 signaling pathways were divergent, in which “No” denotes balanced cAMP and ERK1/2 signaling,
whereas “Yes” denotes biased activation of ERK1/2 signaling. “↑”: denotes increased activity. “↓”: denotes decreased activity. “―”: denotes no signiﬁcant change.
1946 X.-L. Mo, Y.-X. Tao / Biochimica et Biophysica Acta 1832 (2013) 1939–1948cell lines (Fig. 3B–C). A similar ﬁnding that α-MSH induced a tran-
sient ERK1/2 activation in GT1–7 cells, was recently reported [35].
Therefore, our present study and those of others [24,25,35] suggested
that NDP-α-MSH-induced ERK1/2 activation mediated by MC4R
could be cell-line dependent.
AgRP was initially identiﬁed as an orexigenic stimulus, through
competitive binding of melanocortins to the MC4R [10]. AgRP was
later found to be an inverse agonist at the MC4R [37,41], suggesting
that AgRPmight exert its function independently ofmelanocortins. Sev-
eral additional lines of evidence [42,43] revealed that the effects of AgRP
on energy homeostasis could be independent ofmelanocortin signaling.
Our results demonstrated that AgRP(83–132) behaved as a biased ago-
nist activating ERK1/2 signaling in WT and CAM MC4Rs in HEK293T
cells. We also showed that AgRP(83–132) also behaved as an agonist
activating ERK1/2 signaling in GT1–7 cells. The ERK1/2 upstreammedi-
ator has not been determined in the present study and need further
investigation. Some alternative signaling pathways of AgRP have been
identiﬁed recently, including Gi/o or arrestin-dependent pathways
(reviewed in [44]). It has been shown that AgRP mediates a pertussis
toxin-sensitive Gi/o-coupled signaling [45], and moreover Gi/o proteins
can activate the ERK1/2 signaling [46,47]. In addition, it has been
demonstrated that AgRP induces arrestin-mediated MC4R endocytosis
in HEK293 or Cos-1 cells [48]. Therefore, Gi/o proteins or arrestins
might be potential mediators of AgRP induced ERK1/2 phosphorylation
in WT and CAM MC4Rs.
In addition to AgRP, we further tested the potential of other MC4R
inverse agonists, including MCL0020, Ipsen 5i and ML00253764, in
activating ERK1/2 signaling. We found that all these inverse agonists
exhibited agonist efﬁcacy for the ERK1/2 signaling. In other GPCRs,
several antagonists or inverse agonists have been identiﬁed to induce
biased ERK1/2 signaling [49,50]. For example, carvedilol, a nonsubtype-
selective β-adrenergic receptor inverse agonist, has been shown to
mediate a G protein independent, β-arrestin2-dependent ERK1/2 acti-
vation [50]. These results suggested that the dual efﬁcacy of inverse
agonists might be a general concept applicable to other GPCRs.
MCL0020 was ﬁrst described to be a neutral antagonist without af-
fecting basal cAMP activity in COS-1 cells [30]. In the present study,
however, we demonstrated that MCL0020 acted as a partial inverse
agonist decreasing basal cAMP accumulation by 46–85% in HEK293T
cells transiently transfected with WT or CAM MC4Rs. Therefore, the
effect of MCL0020 on MC4R might be cell-line dependent.
In addition to biased ligands, some receptor mutants are intrinsi-
cally biased even when stimulated with traditional balanced ligands
[28,51–53]. In the present study, we demonstrated that the patterns
of biased ERK1/2 signaling in different MC4R mutants varied even in
response to the same ligand. For example, upon Ipsen 5i stimulation
three CAM MC4Rs (P230L, L250Q and F280L) had decreased cAMP
but increased ERK1/2 signaling, whereas WT and other three CAM
MC4Rs (H76R, S127L and D146N) had only decreased cAMP signaling,
but no signiﬁcant change of ERK1/2 activity was observed. ML00253764
activated ERK1/2 signaling in WT and four CAM MC4Rs (D146N, P230L,
L250Q and F280L) but had no effect on ERK1/2 activity in other twoCAMMC4Rs (H76R and S127L). These results suggested that there were
some structural requirements of receptor for ligands to exert their dual ef-
ﬁcacies. Indeed, recent crystal structures of β1-adrenergic receptor [54]
and serotonin receptor [55] proved that the conformation of receptor
bound with biased ligand is different from that with balanced ligand.
Further systematic identiﬁcation of intrinsically biased receptor mutants
might be an alternative way to help in designing more potent biased
ligands.
Conventionally, the constitutive activity of GPCRs was solely
characterized using the G protein dependent signaling. Numerous
CAM GPCRs have been reported to associate with diseases [17].
Even some WT receptors also have considerable constitutive activity
[17,56]. Basal signaling of MC4R might be important for maintaining
energy homeostasis in humans [57]. Paradoxically, several constitu-
tively active mutants were identiﬁed from obese patients (reviewed
in [6]). Increased constitutive activity is expected to result in de-
creased food intake and increased energy expenditure, therefore a
lean phenotype. Herein, we showed that all six CAM MC4Rs had not
only constitutive activity in basal cAMP signaling, but also constitu-
tive activity in basal ERK1/2 signaling. Moreover, the inverse agonist,
AgRP(83–132), exhibited agonist efﬁcacy for ERK1/2 signaling in WT
and CAM MC4Rs. This novel AgRP-mediated ERK1/2 signaling path-
way provided a potential missing link towards a better understanding
of the physiological function of AgRP at the molecular level. Hopeful-
ly, further in vivo study on the ERK1/2 signaling of these naturally
occurring CAM MC4Rs might reveal the pathophysiology of the con-
stitutive activity in MC4R.
It has been demonstrated that MC4R mediates melanocortin-
induced long-lasting effects on regulating food intake and energy
expenditure in rats [58]. ERK1/2 is known to activate transcription
factors to alter gene expression [59]. We suggest that alterations in
basal and/or stimulated ERK1/2 signaling might be mediating the
long-lasting effect of the MC4R and the pathogenesis of the CAM
MC4Rs in human obesity. More studies need to be done to elucidate
the exact mechanisms.
In summary, the results of the present study demonstrated that
several MC4R inverse agonists in the cAMP pathway acted as agonists,
activating ERK1/2 signaling, adding a new layer of complexity to the
MC4R signaling. The study also conﬁrms the multiple activation states
of MC4R with ligand-speciﬁc and/or mutant-speciﬁc conformations
capable of differentially coupling the MC4R to distinct signaling
pathways.
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